WTB RSS
12-19-2011, 01:38 PM
PDL BioPharma expects fourth quarter revenue to fall about 5 percent, the drug developer said Monday, due mainly to reduced royalty payments for the cancer drugs Avastin and Herceptin.For the full year, ...
More... (http://finance.yahoo.com/news/pdl-biopharma-forecasts-5-pct-172400765.html)
More... (http://finance.yahoo.com/news/pdl-biopharma-forecasts-5-pct-172400765.html)